Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet

Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.